Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMT NASDAQ:PHVS NYSE:RCUS NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$6.69-1.6%$5.75$2.23▼$17.41$317.58M2.86550,496 shs465,082 shsPHVSPharvaris$23.81+1.8%$21.99$11.51▼$26.33$1.22B-2.8125,488 shs157,557 shsRCUSArcus Biosciences$11.74+1.4%$10.15$6.50▼$18.98$1.23B0.83715,653 shs566,530 shsSPRYARS Pharmaceuticals$9.41-5.5%$15.13$9.38▼$18.90$984.31M0.873.03 million shs2.31 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-0.15%-2.44%-6.34%+63.86%-58.15%PHVSPharvaris+0.78%+7.10%+4.84%+41.18%+11.76%RCUSArcus Biosciences+0.61%+1.26%+11.36%+32.53%-35.54%SPRYARS Pharmaceuticals-0.70%-6.92%-31.45%-32.79%-25.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$6.69-1.6%$5.75$2.23▼$17.41$317.58M2.86550,496 shs465,082 shsPHVSPharvaris$23.81+1.8%$21.99$11.51▼$26.33$1.22B-2.8125,488 shs157,557 shsRCUSArcus Biosciences$11.74+1.4%$10.15$6.50▼$18.98$1.23B0.83715,653 shs566,530 shsSPRYARS Pharmaceuticals$9.41-5.5%$15.13$9.38▼$18.90$984.31M0.873.03 million shs2.31 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-0.15%-2.44%-6.34%+63.86%-58.15%PHVSPharvaris+0.78%+7.10%+4.84%+41.18%+11.76%RCUSArcus Biosciences+0.61%+1.26%+11.36%+32.53%-35.54%SPRYARS Pharmaceuticals-0.70%-6.92%-31.45%-32.79%-25.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40354.41% UpsidePHVSPharvaris 2.80Moderate Buy$34.0042.80% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1480.09% UpsideSPRYARS Pharmaceuticals 3.14Buy$32.50245.38% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, SPRY, PHVS, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/13/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating9/4/2025SPRYARS PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.008/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/18/2025PHVSPharvarisZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/13/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$55.00 ➝ $52.008/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$26.00 ➝ $25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$33K9,467.77N/AN/A$11.05 per share0.61PHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ARCUSArcus Biosciences$262M4.77N/AN/A$5.30 per share2.22SPRYARS Pharmaceuticals$89.15M10.43N/AN/A$2.64 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)Latest FDMT, SPRY, PHVS, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A8.758.75PHVSPharvarisN/A8.338.33RCUSArcus Biosciences0.184.504.50SPRYARS Pharmaceuticals0.376.175.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%PHVSPharvarisN/ARCUSArcus Biosciences92.89%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics9.60%PHVSPharvarisN/ARCUSArcus Biosciences9.60%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionablePHVSPharvaris3052.29 millionN/ANot OptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableFDMT, SPRY, PHVS, and RCUS HeadlinesRecent News About These CompaniesARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - What's Next?September 14 at 12:11 PM | marketbeat.comWoodline Partners LP Sells 518,961 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 14 at 4:11 AM | marketbeat.comOctagon Capital Advisors LP Buys Shares of 625,000 ARS Pharmaceuticals, Inc. $SPRYSeptember 11, 2025 | marketbeat.comARS Pharmaceuticals announces real-world evidence on neffy effectivenessSeptember 9, 2025 | finance.yahoo.comAlliancebernstein L.P. Has $49.35 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 9, 2025 | marketbeat.comWhat is Roth Capital's Estimate for SPRY Q3 Earnings?September 9, 2025 | marketbeat.comWhat is Roth Capital's Forecast for SPRY Q3 Earnings?September 9, 2025 | americanbankingnews.comReal-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing AnaphylaxisSeptember 8, 2025 | globenewswire.comAlyeska Investment Group L.P. Cuts Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Should You Sell?September 8, 2025 | marketbeat.comTrexquant Investment LP Buys 44,206 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 12-Month Low - What's Next?September 8, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Now Covered by Analysts at Roth CapitalSeptember 7, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated at Roth CapitalSeptember 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Cormorant Asset Management LPSeptember 6, 2025 | marketbeat.comArdsley Advisory Partners LP Takes $4.09 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 5, 2025 | marketbeat.comRoth Capital Initiates Coverage of ARS Pharmaceuticals (SPRY) with Buy RecommendationSeptember 5, 2025 | msn.comARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDASeptember 4, 2025 | msn.comARS Pharmaceuticals initiated with a Buy at Roth CapitalSeptember 4, 2025 | msn.comMPM Bioimpact LLC Acquires New Shares in ARS Pharmaceuticals, Inc. $SPRYSeptember 4, 2025 | marketbeat.comQuarry LP Takes $415,000 Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, SPRY, PHVS, and RCUS Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$6.69 -0.11 (-1.62%) Closing price 04:00 PM EasternExtended Trading$6.72 +0.03 (+0.45%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Pharvaris NASDAQ:PHVS$23.82 +0.45 (+1.90%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Arcus Biosciences NYSE:RCUS$11.74 +0.16 (+1.38%) Closing price 03:59 PM EasternExtended Trading$11.75 +0.01 (+0.09%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.ARS Pharmaceuticals NASDAQ:SPRY$9.41 -0.55 (-5.52%) Closing price 04:00 PM EasternExtended Trading$9.51 +0.10 (+1.05%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
